<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062397</url>
  </required_header>
  <id_info>
    <org_study_id>JPI-289-P2</org_study_id>
    <nct_id>NCT03062397</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic
      Stroke
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infact growth ratio from baseline</measure>
    <time_frame>4 days from baseline</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JPI-289 Low dose or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JPI-289 High dose or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same dosage of JPI-289 low and high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JPI-289 Low-dose</intervention_name>
    <description>JPI-289 Low dose will be intravenously administered during 24 hours</description>
    <arm_group_label>Low-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JPI-289 High-dose</intervention_name>
    <description>JPI-289 High dose will be intravenously administered during 24 hours</description>
    <arm_group_label>High-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with acute ischemic stroke, aging â‰¥ 19

          -  Confirmed to have acute anterior circulation cerebral artery occlusion in intracranial
             internal carotid artery (IICA) or middle cerebral artery (MCA) M1 segment by CT or MR
             angiography.

          -  National Institutes of Health Stroke Scale(NIHSS) is 6~30 before endovascular
             recanalization therapy (ERT)

          -  Subject who is reperfused with 2b or 3 stages of thrombolysis in cerebral infarction
             (TICI) (However, if angiography is conducted for thrombectomy after IV tPA treatment
             and the effect of tPA results in TICI 2b-3 reperfusion, the subject can participate)

          -  Subject who can administer IP within 6.5 hrs of symptom development

          -  Subject who can administer IP within 30 min of vascular reperfusion

          -  Subject who can evaluate MRI within 90 min of vascular reperfusion

        Exclusion Criteria:

          -  Subject who is contraindicated for endovascular recanalization

          -  Subject who has hypersensitivity to contrast agent or component of investigational
             product

          -  Prohibited or unable to perform MRI test

          -  Medical history that is related to bleeding

          -  History of hemorrhagic stroke within 6 months of study participation

          -  Subjects with chronic liver disorder

          -  Kidney disorder (Serum creatinine &gt; 3 mg/dL)

          -  Life expectancy is less than 3 months due to concomitant disease other than stroke

          -  Pregnant or lactating women

          -  Those who have taken tirofiban (anticoagulant agent) during endovascular
             recanalization therapy

          -  Those who have taken other investigational drugs and/or medical instruments 12 weeks
             prior to screening

          -  Subject is unable to be followed up

          -  Subject is deemed unable to participate the study in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Byung Woo Yoon, MD. PhD</last_name>
    <email>bwyoon@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Kwan Cha, MD. PhD</last_name>
      <email>nrcjk65@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Lee, MD. PhD</last_name>
      <email>junlee@ynu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jei Kim, MD. PhD</last_name>
      <email>jeikim@cnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Seok Park, MD. PhD</last_name>
      <email>mspark@chonnam.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Sik Hong, MD. PhD</last_name>
      <email>nrhks@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moon Ku Han, MD. PhD</last_name>
      <email>mkhan@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Seo Kim, MD. PhD</last_name>
      <email>aescula@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Woo Yoon, MD. PhD</last_name>
      <email>bwyoon@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

